Indian journal of dermatology · 2026
Topical 10% Tranexamic Acid in Topical Steroid-Damaged Faces: A Non-Randomised Interventional Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kashyap Pranami, Marak Anita, Verma Shikha, Kumari Sakshi
Аннотация
BACKGROUND: Topical Steroid Damaged/Dependent Face (TSDF) is described as 'the semi-permanent or permanent damage to the skin of the face precipitated by the irrational, indiscriminate, unsupervised, or prolonged use of TCs resulting in a plethora of cutaneous signs and symptoms and psychological dependence on the drug'. Its management is difficult due to the unavailability of a universally accepted treatment regimen, as well as a high rate of rebound after stopping therapy.
AIM: To study the efficacy and safety of the application of 10% tranexamic acid solution in Topical Steroid Damaged/Dependent Faces.
METHODS: In this non-randomised interventional study, 15 cases with TSDF were treated with topical 10% tranexamic acid solution applied once daily for 8 weeks and followed up every 4 weeks up to 12 weeks. Erythema, the hallmark of TSDF, was graded based on the Clinician's Erythema Assessment (CEA) scale, and improvement in this score was recorded at every follow-up visit along with clinical photographs.
RESULTS: Erythema, photosensitivity and telangiectasia were present in all our subjects, followed by pigmentary abnormalities, acneiform eruptions, hypertrichosis and atrophy. Based on the reduction in CEA, we recorded a statistically significant improvement in erythema at week 4, and complete resolution of the same in 100% of our subjects by week 8.
CONCLUSIONS: Topical 10% tranexamic acid solution is a novel, promising, safe and efficacious modality in the treatment of TSDF.
AIM: To study the efficacy and safety of the application of 10% tranexamic acid solution in Topical Steroid Damaged/Dependent Faces.
METHODS: In this non-randomised interventional study, 15 cases with TSDF were treated with topical 10% tranexamic acid solution applied once daily for 8 weeks and followed up every 4 weeks up to 12 weeks. Erythema, the hallmark of TSDF, was graded based on the Clinician's Erythema Assessment (CEA) scale, and improvement in this score was recorded at every follow-up visit along with clinical photographs.
RESULTS: Erythema, photosensitivity and telangiectasia were present in all our subjects, followed by pigmentary abnormalities, acneiform eruptions, hypertrichosis and atrophy. Based on the reduction in CEA, we recorded a statistically significant improvement in erythema at week 4, and complete resolution of the same in 100% of our subjects by week 8.
CONCLUSIONS: Topical 10% tranexamic acid solution is a novel, promising, safe and efficacious modality in the treatment of TSDF.